News from IAS 2017

The 9th IAS Conference on HIV Science (IAS 2017) is taking place in Paris, France, in July.

We will be reporting on key research presented at the conference, publishing news online and sending out news summary bulletins by email.

“The coverage made me feel I was at the conference and I appreciate NAM's effort in sharing the bulletins.” NAM bulletin subscriber

aidsmap news from IAS 2017

Experts concur that event-related oral PrEP probably won’t work for women

Two presentations at the recent International AIDS Society Conference on HIV Science (IAS 2017) in Paris told delegates that both trial results and analysis of drug

Published
01 September 2017
By
Gus Cairns
Who are trans women acquiring HIV from?

There is a lot we don’t know about trans women’s HIV risk, why they are so vulnerable to HIV and who trans women are acquiring HIV

Published
29 August 2017
By
Gus Cairns
One in seven people offered PrEP in African study start it immediately

One in seven people (14%) offered pre-exposure prophylaxis (PrEP) in a large community study of enhanced HIV testing and treatment in Kenya and Uganda started

Published
28 August 2017
By
Gus Cairns
Trans women wary of antiretroviral drug and hormone interactions

Transgender women living with HIV may be hesitant to use antiretroviral therapy (ART) or not take it as prescribed because of concerns about drug interactions with feminising hormones,

Published
23 August 2017
By
Liz Highleyman
People with HIV are at risk for liver fibrosis and steatosis

Metabolic syndrome, type 2 diabetes and obesity are risk factors for the development of liver fibrosis and steatosis (liver fat accumulation) in people living with

Published
21 August 2017
By
Liz Highleyman
Peripheral artery disease more common in people with HIV with lower CD4 counts

Peripheral artery disease, one of the most common forms of cardiovascular disease, occurs more frequently in people with HIV who have CD4 cell counts below

Published
15 August 2017
By
Keith Alcorn
PrEP use in US exceeds 100,000 in Gilead pharmacy survey

An estimated 120,000 people in the US have started Truvada for pre-exposure prophylaxis (PrEP) since 2012, according to the latest findings from a survey of

Published
14 August 2017
By
Liz Highleyman
Switch from boosted protease inhibitor to dolutegravir reduces lipids in people with HIV at higher risk of heart disease

Switching from a boosted protease inhibitor to the integrase inhibitor dolutegravir was associated with lipid reductions in people with HIV at higher risk of heart

Published
09 August 2017
By
Keith Alcorn
Boosted darunavir plus lamivudine matches three-drug regimen

A combination of darunavir/ritonavir and lamivudine was just as effective as the same combination plus tenofovir, according to 24-week results of the ANDES study presented

Published
08 August 2017
By
Keith Alcorn
Why curing HIV may be like curing cancer – and may be as difficult

For the last few years, a specialist symposium on HIV cure research has preceded the International AIDS Society (IAS) Conferences and this one was no exception,

Published
03 August 2017
By
Gus Cairns
← First12345Next →

Email bulletins

Sign up for our conference bulletins

Find out more and sign up to the full range of aidsmap email bulletins >

Tweets from IAS 2017

  • Zero HIV transmission in gay sex when virally suppressed, 40k condomless sex acts. End of debate? Think so. #IAS2017 https://t.co/7aR6JjdVVq27 Jul 2017 03:47
  • A long-acting #PrEP, injected every 8 weeks, shows promise. If effective, it could be a game changer. #IAS2017: https://t.co/k3Gs6ISAEW27 Jul 2017 01:38
  • #IAS2017 was great! We have come far in the fight against #HIV (e.g., #PrEP) but we have a long way to go (e.g., #EndStigma) + more funding27 Jul 2017 10:38
  • #IAS2017 finished yestareday with over 7800 participants. Basic research sessions offered excellent science and had impressive attendance.27 Jul 2017 10:32
  • Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows https://t.co/vSq1fWhqwP #IAS201727 Jul 2017 10:14
  • South Africa will be producing generic #dolutegravir for the region #IAS2017 @AfrocabH27 Jul 2017 10:13
  • "Meaningful involvement of #keypopulations and #PLHIV in shaping research priorities must remain an unwavering principle." #IAS2017 #HIV26 Jul 2017 08:30
  • M. Lichterfeld at #IAS2017, in basic science rapporteur session, reaffirms that early #HIV testing can better prevent infection spread.26 Jul 2017 05:46
  • O.Mellouk @ITPCglobal: Gilead pricing wrecked countries' budgets & forced people to run from country to country to get sofosbuvir #IAS201726 Jul 2017 05:32
  • Demonstration projects explore the feasibility of PrEP for adolescents and young women in South Africa https://t.co/cIy5MaPhT8 #IAS201726 Jul 2017 05:18
  • The first slides from #IAS2017 have been uploaded to https://t.co/MZA7a9bCpr many many more to come. Free access, register now...26 Jul 2017 05:07
  • "Better feedback between #keypops & providers leads to accountability & continuous quality improvement." - Cameron Wolf @USAIDGH #IAS201726 Jul 2017 03:20
  • @WHO endorses that buyer's clubs can be seriously considered for getting access to drugs when all other options are unaffordable #IAS201726 Jul 2017 03:05
  • #IAS2017 #ambassadorBirx on #HSS & #hiv response: we didn't just strengthen existing health systems, we needed to create what did not exist26 Jul 2017 03:03
  • In #Kenya we’re creating demand for #HIV services among young women through peer edu & innovative methods like television programs. #IAS201726 Jul 2017 03:00
  • "Investments in research &prevention tools are key but we need to understand why existing ones aren't being used" @MarijkeWijnroks #IAS201726 Jul 2017 02:41
  • To make drugs affordable for all, we work with the MPP and its voluntary licensing model - Jessica Burry from @MSF_access #IAS2017 #EndAIDS26 Jul 2017 02:11
  • "We must make [#HIV] facility-based services more acceptable, accessible, affordable, & equitable." - Kate Thomson @GlobalFund #IAS2017 #KPs26 Jul 2017 02:01
  • Among Kenyan/Ugandan women at high HIV risk, contraceptive use didn't appear to impact PrEP adherence #IAS2017 https://t.co/FW9iDVSwE726 Jul 2017 01:51
  • "Le travail des gouvernements est de négocier les prix des médicaments, pas juste d'enregistrer ces prix". #IAS201726 Jul 2017 01:43
  • New #HIV vaccine meets the criteria to start large scale phase III human trials this year. #IAS2017 https://t.co/HV2wzWk3v826 Jul 2017 01:30
  • Confidence d'un chercheur du Malawi (HIV/Tuberculose) "c'est dur de voir les gens mourir de maladies qu'on peut prévenir." #IAS201726 Jul 2017 01:05
  • There has been a tremendous increase in uptake of #hivselftest but more pronounced increase in women - Karin Hatzold @PSIimpact #ias201726 Jul 2017 12:50
  • Unacceptable that 18% of 27000 HIV-related TB cases died in Europe in 2015. Living with #HIV. Dying from #TB @HIVTB @HarmReduction #IAS201726 Jul 2017 12:21
  • Hanne Zimmermann's presentation on motivations for event-driven vs. daily #PrEP use in #Dutch men is excellent. And she's cool #ias201726 Jul 2017 11:26
  • #TB screening of pregnant women living with HIV increased TB detection 10x & reduced infant mortality in #SouthAfrica #IAS201726 Jul 2017 11:22
  • Lots of #IAS2017 sessions have been filmed and are being published on the @IAS_conference YouTube channel: https://t.co/OgzOR1MTFv26 Jul 2017 09:22
  • Fantastic session on #women & #HIV-from #PMTCT to #menopause.Much work to be done to increase inclusion of women in HIV research #IAS201726 Jul 2017 11:12
  • Coceka Mnyani: #HIV remains leading cause of death for women aged 30-49 globally #IAS201726 Jul 2017 10:25
  • Interesting to hear more about 4-5 days a week ART, from Anna Turkova of @MRCCTU and GOSH... #IAS201726 Jul 2017 10:18
  • Ayesha of CAPRISA: voluntary male circumcision not only protects men, it also reduces chances of women contracting #HIV and #Herpes #ias201726 Jul 2017 10:17
  • Ipergay trial: PrEP still protected people who had less sex and used it less often https://t.co/DDV5Vz7CFp #IAS201726 Jul 2017 09:57
  • PADDLE "small numbers but strong message". No. Small numbers = weak message. Too often we learn pilots are not always replicated #IAS201726 Jul 2017 10:12
  • International study of gay couples reports no transmissions from an #HIV-positive partner on treatment https://t.co/YevmhHhsZ3 #IAS201725 Jul 2017 03:28
  • "When #keypopulations are ignored or stigmatized, #HIV spreads." - @LindaGailBekker #IAS2017 @iasociety @DTHF_SA25 Jul 2017 03:01
  • Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection https://t.co/uwJ1gE9Zxz #IAS201726 Jul 2017 09:57
  • Young people are not a homogenous group and we can't expect to reach them with a one-size-fits-all approach -@ygpillay #IAS2017 #youth26 Jul 2017 09:46
  • Fabien Zoulim: #HBV viral replication can continue in liver despite 'viral suppression,' explains need for lifelong #hepB therapy #IAS201726 Jul 2017 09:19
  • Alexandra Calmy: As middle-income countries shift away from efavirenz, expanding access to generic drugs for #HIV is indispensable #IAS201726 Jul 2017 08:50
  • Women represent less than 20% of #HIV drug trial participants. #IAS201726 Jul 2017 08:45
  • Can self testing engage 'hard to reach' men with HIV testing? #IAS2017 https://t.co/xklhqs3Xgd26 Jul 2017 08:06
  • 12000 insertive sex msm, 0 transmissions in couples, 3 from outside, tasp and varying degrees of prep #IAS201725 Jul 2017 02:43
  • Dr. Gotham: $90 per person can be new ceiling price for treating #HIV, #TB, #HCV & #HBV. #IAS2017 @HIVpxresearch @IAS_conference25 Jul 2017 02:42
  • #IAS2017: AIDS-related deaths comprise 54% of overall inpatient deaths in Nsanje hospital, #Malawi. Of these 29% occur within first 48 hours25 Jul 2017 02:15
  • New @WHO guidance says start #HIV treatment within 7 days of diagnosis - & at once if patient is willing. #IAS2017 https://t.co/2XYY4mvLun25 Jul 2017 02:13
  • #IAS2017 #MSF calls for the wide implementation of new WHO guidelines for advanced HIV and strengthened hospital-based care.25 Jul 2017 01:42
  • French #PrEP Ipergay trial found 29% of participants report at least one occasion of #Chemsex, also associated with high risk sex. #IAS201725 Jul 2017 02:03
  • #IAS2017 #MSF: While increased access to ART has led to reduced deaths, these gains have been limited for those people with advanced HIV.25 Jul 2017 01:39
  • "La situation du #Sida en Europe de l'est est catastrophique, on peut le dire" Michel #Kazatchkine #ONU #IAS201725 Jul 2017 01:36
  • New integrase inhibitor bictegravir works well for first-line HIV treatment https://t.co/AutuZRfCRu25 Jul 2017 08:51
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.